eliemtx.com (ELYM) Price to Earnings Ratio

Eliem - graphic logo of issuer ELYM

Risks of delays in the development of neuropsychiatric agents and funding shortages have been partially offset by merger deals. This price chart illustrating trading dynamics with the -5.40 indicator complements data on the recruitment of leading neurobiologists through bonuses and the scientific expertise of top management. Eliem Therapeutics (ELYM) relies on the creation of innovative medications for depression and chronic pain with a gentler impact on the body.

Eliem Therapeutics, Inc. (ELYM) P/E Multiple: for the period 07/04/2022 - 10/03/2024

Analytical breakdowns for eliemtx.com (ELYM)

- market price and analyst price targets:
General company analysis:Eliem Therapeutics Inc., ELYM
Signature product of Eliem Therapeutics

The P/E ratio determines the market value of a single unit of profit, measuring the extent to which investors are overpaying for current earnings. High values signal expectations of expansion, while low values indicate undervaluation or risks. By analyzing the P/E dynamics of an issuer, one can track shifts in capital sentiment regarding future growth rates. For Eliem Therapeutics (ELYM), this indicator remains stable, as the development of drugs for neurological pathologies does not depend on consumer cycles.

Key competitors

Price to Earnings Ratio BIIB|P/E Multiple NBIX|Regencell (RGC) - Market Cap to Net Income Ratio|Price to Earnings Ratio axsome.com AXSM|P/E Multiple ACADIA Pharmaceuticals ACAD|XENE - Price to Earnings Ratio|Business Payback Period Viking Therapeutics Inc VKTX|Supernus Pharma (SUPN) - Price to Earnings Ratio|CPRX (Catalyst Pharmaceuticals) - Price to Earnings Ratio|DNLI (denalitherapeutics.com) - P/E Multiple|Price to Earnings Multiple HRMY (Harmony Biosciences Holdings, Inc.)|P/E Multiple BHVN|AMLX (Amylyx Pharmaceuticals Inc) - Company Value to Net Income|P/E Multiple TRVI (Trevi Pharma)|PRAX (Praxis Corp) - Market Cap to Net Income|anavex.com - P/E Multiple|Company Value to Net Income CBLL (CeriBell, Inc.)|PRTA: P/E Multiple|Price to Earnings Multiple ALEC|ANNX (Annexon Biosciences Inc.) - P/E Multiple|omeros.com - Market Cap to Net Income|Price to Earnings Ratio Neurogene (NGNE)|Business Payback Period AC Immune SA|P/E Multiple VYGR (voyagertherapeutics.com)|P/E Multiple Neumora NMRA|Scilex Holding - P/E Multiple|Market Cap to Earnings Tevogen Bio Inc.|Alpha Cognition (ACOG) - Price to Earnings Ratio|cogrx.com (CGTX) - P/E Multiple|Price to Earnings Ratio Inhibikase Therapeutics|Cassava (SAVA) - Business Payback Period|Price to Earnings Ratio Assertio Therapeutics (ASRT)|Business Payback Period Coya|Vistagen - Price to Earnings Ratio|Company Value to Net Income OVID|Acumen Pharmaceuticals Inc. - P/E Multiple|Market Cap to Earnings CervoMed Inc|ATHE: P/E Multiple|Price to Earnings Ratio Clene Nanomedicine|Price to Earnings Ratio PepGen Corp|Jupiter Neurosciences (JUNS) - Business Payback Period|Price to Earnings Ratio Relmada Therapeutics, Inc. (RLMD)|ANVS - Market Cap to Earnings|gracetx.com - Price to Earnings Ratio|AIFF: Price to Earnings Multiple|Klotho Neurosciences - P/E Multiple|NRSN (NeuroSense Therapeutics Ltd.) - Price to Earnings Multiple|Reviva Pharmaceuticals (RVPH) - Price to Earnings Ratio|MTVA (MetaVia Inc.) - Price to Earnings Ratio|Price to Earnings Ratio NeurAxis, Inc|Price to Earnings Ratio HSDT|P/E Multiple PASG|Business Payback Period Neuphoria Therapeutics, Inc.|minervaneurosciences.com - Price to Earnings Ratio|P/E Multiple Athira ATHA|Addex Therapeutics - P/E Multiple|ALZN - P/E Multiple|Cyclerion (CYCN) - Price to Earnings Ratio|Protagenic (PTIX) - P/E Multiple|Price to Earnings Ratio Pasithea|Price to Earnings Multiple CRGT (Cortigent)|Price to Earnings Ratio Avenue Therapeutics (ATXI)|BCLI - Market Cap to Earnings|P/E Multiple CARA (Cara Therapeutics Inc)|CHRO - Price to Earnings Ratio|Intra-Cellular Therapies Inc. - P/E Multiple|Market Cap to Earnings Longboard Pharmaceuticals Inc|Marinus (MRNS) - Price to Earnings Ratio|NKGN - Business Payback Period|Price to Earnings Ratio NeuroBo Pharmaceuticals|SAGE: Company Value to Net Income|P/E Multiple SNPX|Trevena Inc. - Price to Earnings Multiple|Price to Earnings Ratio Vigil Neuroscience, Inc. VIGL|Anew Medical, Inc. - Price to Earnings Ratio|Cerevel Therapeutics - P/E Multiple